RET and non-small cell lung carcinoma: An ongoing phase III trial (NCT04194944) [78] is evaluating selpercatinb versus platinum-based chemotherapy (CT) with or without immunotherapy (IT) in treatment-naïve patients with advanced RET-fusion positive NSCLC.